

An Overview of Pharmacologic Treatments Under Investigation for Long COVID

Roxane Rohani, PharmD, MSc, BCACP
Assistant Professor of Pharmacology
Chicago Medical School
Rosalind Franklin University of Medicine and Science

Disclosure Statement

The speaker has no conflicts of interest or relationships with commercial entities that may be referenced in this presentation.

1

2

Learning Objective

- Discuss pharmacologic treatment options under investigation in various clinical trials for Long COVID

Definition of Long COVID

- AKA: 'post-COVID-19', 'long-haul covid', 'post-acute sequelae of COVID-19 (PASC)', 'ongoing COVID-19', 'chronic Covid syndrome'
- Prolonged/ residual COVID-19 symptoms lasting more than 4 weeks OR
- Relapsing/ new symptoms \geq 30 days after acute infection





3

4

Prevalence of Long COVID

- 45% of individuals with \geq 1 unresolved symptom (at ~ 4 months)
 - Hospitalized patients: 52.6%
 - Non-hospitalized patients: 34.5%
- Few people have full recovery
 - 85% of those w/ symptoms 2 months after acute infection, had symptoms 1 year after symptom onset

Symptoms of Long COVID

- \geq 60 physical & psychological symptoms
 - Fatigue, brain fog, postexertional malaise, dizziness 
 - Palpitations, chest pain 
 - Breathlessness, chronic cough 
 - Loss of or change in smell or taste 
- Others: sleep disturbance, GI symptoms, changes in sexual desire, thirst, abnormal movements

5

6

Pathogenesis of Long COVID

- Persisting viral reservoirs in tissues
- Immune dysregulation
- Autoimmunity
- Changes in gut microbiota
- Microvascular blood clotting with endothelial dysfunction
- Signaling dysfunction in brainstem/ vagal nerve

2023 ICHP ANNUAL MEETING

Data: H.C. McCullough, L. et al. 2023 Mar 23(25):1331-1341 PMID: 36879608

7

Pharmacological Treatments Under Investigation in Clinical Trials

2023 ICHP ANNUAL MEETING

8

Core Symptoms

2023 ICHP ANNUAL MEETING

9

Nirmatrelvir/Ritonavir

- **Trial registration#** NCT05668091
- **Study design:** randomized, double-blind
- **Inclusion:** highly symptomatic adults with long COVID
- **Intervention:** Nirmatrelvir 2x150 mg tab Q12h + Ritonavir 1X100 mg cap Q12h for 15 days
- **Primary outcome:**
 - Physical Health Summary Score (depression, physical function, pain interference, fatigue, sleep disturbance, satisfaction with participation in social roles)

2023 ICHP ANNUAL MEETING

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05668091> Accessed August 5, 2023

10

Nirmatrelvir/Ritonavir (cont'd)

- **Trial registration#** NCT05576662
- **Study design:** randomized, double-Blind
- **Inclusion:**
 - ≥ 2 long COVID symptoms (fatigue, brain fog, shortness of breath, GI or CV symptoms) persisting > 3 months
- **Intervention:** Nirmatrelvir 2x150 mg tab Q12h + Ritonavir 1X100 mg cap Q12h for 15 days
- **Primary outcome:**
 - Core Symptoms Severity Scale Score (fatigue, brain fog, dyspnea, body aches, gastrointestinal symptoms, cardiovascular symptoms)

2023 ICHP ANNUAL MEETING

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05576662> Accessed August 5, 2023

11


Remdesivir

- **Trial registration#** NCT04978259
- **Study design:** randomized, open label
- **Inclusion:** alive patients who attended the SOLIDARITY Finland sub-study (w/ confirmed COVID infection + were admitted to hospital/ICU)
- **Intervention:** remdesivir IV during hospital stay up to 10 days
- **Primary outcome:** effect on long-COVID symptoms & quality of life at 1 and 2 years post-discharge

2023 ICHP ANNUAL MEETING

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT04978259> Accessed August 4, 2023

12




Vitamin K2 & Vitamin D3

- **Trial registration#** NCT05356936
- **Study design:** randomized, open label
- **Inclusion:**
 - Diagnosed with COVID-19 \geq 3 months ago
 - With persistent, recurrent or even new long COVID symptoms
- **Intervention:** Vitamin K2 and Vitamin D3 by mouth daily
- **Primary outcome:** Effects on Inflammatory Biomarkers

2023 ASCO ANNUAL MEETING <https://doi.org/10.1200/JCO.2023.41.1616> Abstract August 7, 2023

13




Metformin

- **Trial registration#** NCT04510194
- **Study design:** randomized, quadruple-blind
- **Inclusion:**
 - Adults, overweight/ obese
 - Documented SARS-CoV-2 positive within 3 days before enrolment
- **Intervention:**
 - Metformin administered within 3 days of symptom onset
 - Dose was titrated over 6 days: 500 mg on day 1, 500 mg BID on days 2–5, then 500 mg in AM and 1000 mg in PM up to day 14
- **Primary outcome:** metformin reduced incidence of long COVID by \sim 41%

2023 ASCO ANNUAL MEETING <https://doi.org/10.1200/JCO.2023.41.1617> Abstract August 7, 2023


14

Neurocognitive Impairment



2023 ASCO ANNUAL MEETING <https://doi.org/10.1200/JCO.2023.41.1618> Abstract August 7, 2023

15




Baricitinib

- **Trial registration#** NCT05858515
- **Study design:** randomized, double blind
- **Inclusion:** documented COVID infection + neurocognitive symptoms for \geq 60 days prior to screening
- **Intervention:** baricitinib 4 mg tab daily for 12 weeks
 - Dose adjusted for renal dysfunction (to 2 mg or 1 mg)
- **Primary outcome:** Global Neuropsychological Function

2023 ASCO ANNUAL MEETING <https://doi.org/10.1200/JCO.2023.41.1619> Abstract August 8, 2023

16




Fluvoxamine

- **Trial registration#** NCT05874037
- **Study design:** randomized, double blind
- **Inclusion:** COVID infection \geq 3 months ago + long COVID neurocognitive symptoms (e.g., brain fog)
- **Intervention:**
 - One dose of fluvoxamine 25mg, then one dose of 50mg, then one dose of 100mg
 - Assessment of subjective reaction to these test doses then randomize to individually tailored course of fluvoxamine for 16 weeks
- **Primary outcome:** improvement in long COVID symptoms (cognitive performance)

2023 ASCO ANNUAL MEETING <https://doi.org/10.1200/JCO.2023.41.1620> Abstract August 7, 2023

17




Vortioxetine

- **Trial registration#** NCT05047952
- **Study design:** randomized, double-blind
- **Inclusion:** COVID infection > 3 months ago + symptoms persisting for \geq 2 months
- **Intervention:**
 - Adults 18–64 yrs old: vortioxetine 10 mg daily for 2 weeks, then dosed up to 20 mg daily for weeks 2–8
 - Adults 65+ years: vortioxetine 5 mg daily for 2 weeks, then dosed up to 10 mg daily for weeks 2–8
- **Primary outcome:** Changes in cognitive function

2023 ASCO ANNUAL MEETING <https://doi.org/10.1200/JCO.2023.41.1621> Abstract August 7, 2023

18




Lithium

- **Trial registration#** NCT05618587
- **Study design:** randomized, double-blind
- **Inclusion:** positive COVID test + symptoms of brain fog/fatigue
- **Intervention:** lithium 10mg PO daily for 3 weeks
- **Primary outcome:** effects on brain fog and fatigue

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05618587> | Annotated August 7, 2023

19




Atorvastatin

- **Trial registration#** NCT04904536
- **Study design:** randomized, open label
- **Inclusion:** adults, COVID diagnosis + persisting neurological symptoms (impairment in memory, concentration, mood)
- **Intervention:** atorvastatin 40mg daily for 18 months
- **Primary outcome:** improvement in neurocognitive function

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT04904536> | Annotated August 7, 2023

20




Nicotinamide Riboside

- **Trial registration#** NCT04809974
- **Study design:** randomized, double-blind
- **Inclusion:** COVID infection \geq 2 months ago + persisting brain fog (and other neurological/ physical symptoms)
- **Intervention:** Niagen (Nicotinamide Riboside, Vitamin B3) 2000mg capsules daily
- **Primary outcome:** improvement in cognitive function, mood, physical health

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT04809974> | Annotated August 7, 2023


21



Chronic Fatigue Syndrome

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05618587> | Annotated August 7, 2023

22




Naltrexone

- **Trial registration#** NCT05430152
- **Study design:** randomized, double-blind
- **Inclusion:** confirmed COVID infection + clinical diagnostic criteria for post-COVID fatigue syndrome
- **Intervention:** Low-Dose Naltrexone as a compounded capsule:
 - Week 1: 1 mg/day (1 mg cap)
 - Week 2: 2 mg/day
 - Week 3: 3 mg/day
 - Weeks 4-16: 4.5 mg/day
- **Primary outcome:** fatigue intensity, decline in levels of inflammatory markers

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05430152> | Annotated August 7, 2023

23




Pregabalin

- **Trial registration#** NCT05967052
- **Study design:** randomized, double-blind
- **Inclusion:** documented COVID infection \geq 6 months ago + diagnosis criteria of post-COVID chronic fatigue syndrome
- **Intervention:** pregabalin 75 to 300 mg daily + comprehensive rehabilitation for 6 months
- **Primary outcome:** change in fatigue intensity, walking distance

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05967052> | Annotated August 7, 2023

24




Probiotics

- **Trial registration#** : NCT05975034
- **Study design**: randomized, double-blind
- **Inclusion**: persistent long COVID symptoms \geq 3months after COVID infection
- **Intervention**: Probiotic taken daily for 12 weeks
 - Participants will use app to track symptoms for 3 weeks before study + last 3 weeks of treatment
- **Primary outcome**: fatigue severity

ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT05975034> Accessed August 7, 2023


25



Respiratory Symptoms

ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT04818489> Accessed August 7, 2023

26




Montelukast

- **Trial registration#** NCT04695704
- **Study design**: randomized, double-blind
- **Inclusion**: documented COVID infection + persistent respiratory symptoms, mild-moderate dyspnea
- **Intervention**: montelukast 10 mg daily for 28 days
- **Primary outcome**: respiratory symptoms

ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT04695704> Accessed August 7, 2023

27




Colchicine

- **Trial registration#** NCT04818489
- **Study design**: randomized, open label
- **Inclusion**: confirmed COVID infection
- **Intervention**: Colchicine 2x0.5 mg BID (loading dose), then 1x0.5mg BID for 3 weeks
- **Primary outcome**: Pulmonary fibrosis

ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT04818489> Accessed August 7, 2023

28




Pirfenidone

- **Trial registration#** NCT04607928
- **Study design**: randomized, double blind
- **Inclusion**: recovered from severe COVID pneumonia + fibrotic lung sequelae
- **Intervention**: pirfenidone 2x267 mg cap Q8hr for 1 week, then if tolerated, increase to 3x267 mg cap Q8hr for 24 weeks
- **Primary outcome**: changes in pulmonary fibrosis

ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT04607928> Accessed August 7, 2023


29



Cardiovascular Symptoms

ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT04818489> Accessed August 7, 2023

30




Metoprolol Succinate

- **Trial registration#** NCT05096884
- **Study design:** single group assignment, open label
- **Inclusion:** documented PCR positive COVID infection + tachycardia/dyspnea with minimal activity
- **Intervention:** metoprolol succinate 25 mg daily for 2 weeks, then if well tolerated every 2 weeks to a max dose of 400 mg daily for 8 weeks
- **Primary outcome:** Change in 6 minute walk test, cardiac function, quality of life

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05096884> Accessed August 7, 2023

31




Efgartigimod

- **Trial registration#** NCT05633407
- **Study design:** randomized, double blind
- **Inclusion:** new-onset postural orthostatic tachycardia syndrome post-COVID
- **Intervention:** efgartigimod IV infusion 10mg/kg weekly for 24 weeks
- **Primary outcome:** reduction in severity of long COVID postural orthostatic tachycardia syndrome

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05633407> Accessed August 7, 2023

32




Coenzyme Q compound

- **Trial registration#** NCT05373043
- **Study design:** non-randomized, double blind
- **Inclusion:** positive COVID test \geq 3 months ago + long COVID symptoms
- **Intervention:** Exercise + Mito-Q (Mitoquinone) vs. Exercise + Placebo
- **Primary outcome:** improvement in vascular endothelial function

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05373043> Accessed August 7, 2023


33



Sensory Symptoms

2023 ICHP ANNUAL MEETING

34




Gabapentin

- **Trial registration#** NCT05184192
- **Study design:** randomized, double blind
- **Inclusion:** recovered from COVID infection + within 2 weeks, experienced post-COVID olfactory dysfunction for \geq 3 months
- **Intervention:**
 - gabapentin, week 1: 300mg TID, week 2: 600mg TID, week 3: 900mg TID, week 4: 1200mg TID
 - then fixed dose (highest tolerable dose) for 8 weeks
 - then taper down for 2 weeks
- **Primary outcome:** improvement in olfactory function

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05184192> Accessed August 7, 2023

35




Pimozide

- **Trial registration#** NCT05507372
- **Study design:** randomized, double blind
- **Inclusion:** tinnitus after COVID infection, persisting for \geq 4 weeks
- **Intervention:** pimozide 1mg
- **Primary outcome:** treatment of COVID induced tinnitus

ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/study/NCT05507372> Accessed August 7, 2023


36



Polling Question!

2023 CACP ANNUAL MEETING

37




Polling Question 1

➤ Which dietary supplement(s) is/are under investigation for management of long COVID symptoms?

- a) Coenzyme Q
- b) Vitamin B3
- c) Vitamin D3
- d) Vitamin K2
- e) All of the above

2023 CACP ANNUAL MEETING

38




Key Takeaways

- ✓ Symptoms ≥ 30 days after acute infection
 - Fatigue, brain fog, palpitations, breathlessness
 - Involves one or multiple organs
- ✓ Pathogenesis/possible treatment options:
 - Persisting viral reservoirs in tissues => antivirals
 - Immune dysregulation => JAK inhibitors
 - Changes in gut microbiota => probiotics
 - Endothelial dysfunction => β-blockers
 - Signaling dysfunction in brainstem/ vagal nerve => antidepressants

2023 CACP ANNUAL MEETING

39




References

- Thaweechai T, et al. AS; RECOVER Consortium. JAMA. 2023 Jun 13;329(22):1934-1946. PMID: 37278994.
- O'Mahoney LL, et al. EclinicalMedicine. 2022 Dec 1;55:101762. PMID: 36474804
- Davis HE, McCorkell L, et al. 2023 Mar;21(3):133-146. PMID: 36639608
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05668091?cond=NCT05668091&draw=2&rank=1>. Accessed August 3, 2023
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT0576662?cond=NCT0576662&draw=2&rank=1>. Accessed August 3, 2023
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT04978259>. Accessed August 4, 2023
- ClinicalTrials.gov <https://clinicaltrials.gov/study/NCT05858515>. Accessed August 4, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05356936?term=vitamin+d&cond=long+covid+or+post+covid&draw=2&rank=1>. Accessed August 7, 2023
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05697640?term=Vericiguat&cond=COVID-19&draw=2&rank=1>. Accessed August 7, 2023
- Bramante CT, et al. Lancet Infect Dis. 2023 Jun 8;S1473-3099(23)00299-2. PMID: 37302406.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05874037?term=Fluvoxamine&cond=long+covid+or+post+covid&draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05047952?term=Vortioxetine&cond=long+covid+or+post+covid&draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05618587?term=lithium&cond=long+covid+or+post+covid&draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT04904536>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT04809974?draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05124563?term=Allogenic+HB-adMSCs&cond=covid&draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05096884>. Accessed August 7, 2023.

2023 CACP ANNUAL MEETING

40




References

- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05481177?term=pharmacologic+treatment&cond=long+covid+or+post+covid&draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05633407?term=Elgartimod&cond=COVID-19&draw=2&rank=2>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05373043?term=Mitoquinone&cond=covid&draw=2&rank=3>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT04818489>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05926505?term=anakinra&cond=long+covid+or+post+covid&draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://clinicaltrials.gov/study/NCT04695704>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT04657484>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT04607928?term=Pirfenidone&cond=covid&draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05430152?term=maltrexone&cond=long+covid+or+post+covid&draw=2&rank=2>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05967052?term=pregabalin&cond=long+covid+or+post+covid&draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05975034?term=probiotic&cond=COVID-19&draw=2&rank=23>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05184192?cond=NCT05184192&draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05507372?term=pimozide&cond=COVID-19&draw=2&rank=1>. Accessed August 7, 2023.
- ClinicalTrials.gov <https://classic.clinicaltrials.gov/ct2/show/NCT05690503?term=pharmacologic+treatment&cond=long+covid+or+post+covid&draw=2&rank=12>. Accessed August 7, 2023.

2023 CACP ANNUAL MEETING

41



Questions?

Roxane Rohani, PharmD, MSc, BCACP
 Assistant Professor of Pharmacology
 Chicago Medical School
 Rosalind Franklin University of Medicine and Science
 North Chicago, IL

2023 CACP ANNUAL MEETING

42